Short Interest in Genprex (NASDAQ:GNPX) Grows By 121.9%

Genprex (NASDAQ:GNPX) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 1,121,624 shares, a growth of 121.9% from the April 15th total of 505,519 shares. Approximately 10.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,951,059 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analysts Forecast Growth

GNPX has been the topic of a number of recent analyst reports. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Genprex currently has an average rating of “Sell”.

Institutional Investors Weigh In On Genprex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mayflower Financial Advisors LLC bought a new stake in Genprex during the first quarter worth approximately $36,000. Manchester Financial Inc. bought a new stake in Genprex during the first quarter worth approximately $36,000. Finally, Susquehanna International Group LLP raised its holdings in Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after purchasing an additional 35,661 shares in the last quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Stock Down 3.6%

Shares of NASDAQ GNPX opened at $0.83 on Friday. Genprex has a fifty-two week low of $0.81 and a fifty-two week high of $55.00. The firm’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $2.40. The stock has a market cap of $8.79 million, a P/E ratio of -0.03 and a beta of -0.94.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.